Voyager Therapeutics (VYGR) Stock Price, Quote, News & History | Benzinga

Voyager Therapeutics Inc (VYGR) Stock Price, Quote, News & History

VYGRNASDAQ

Trade with Public

Trade with Public

$3.48

0.041.16%

At close: Aug 25, 5:00 PM EST

$3.48

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.45

Close

$3.48

Volume / Avg.

306.50K / 604.59K

Day Range

$3.45 - $3.56

52 Wk Range

2.94 - 5.55

Market Cap

$210.27M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

61

Short Interest

7.08%

Days to Cover

5.85

Recent Voyager Therapeutics, Inc. News

Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial Stock

Jim Cramer recommended buying GE Vernova Inc. as Bernstein analyst initiated coverage with an Outperform rating and $1,206 price target.

Avi Kapoor

J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline

Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for next-generation tau-targeting drug programs.

Vandana Singh

Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst

Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target.

Vandana Singh

Puma Biotechnology's Q1 Earnings and Revenues Beat

Puma Biotechnology, Inc. (NASDAQ: PBYI) reported first-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, the company had reported adjusted earnings of 9 cents.

Zacks

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term value.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-120.57M

Investing Cash Flow (TTM)

105.80M

Financing Cash Flow (TTM)

6.46M

Free Cash Flow (TTM)

-121.42M

Capital Expenditure (TTM)

-847.00K

Net Change in Cash (TTM)

-8.31M

Analyst Trends and Forecast

1

Mar

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$127.89M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

5.93

PB Ratio (TTM)

1.37

Earnings Yield % (TTM)

-52.69%

Earnings Yield % (FWD)

-46.00%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.51

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$35.77M

Debt to Equity

0.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.45

Close

$3.48

Volume / Avg.

306.50K / 604.59K

Day Range

$3.45 - $3.56

52 Wk Range

2.94 - 5.55

Market Cap

$210.27M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

61

Short Interest

7.08%

Days to Cover

5.85

About

Sector

Health Care

Industry

Biotechnology

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Voyager Therapeutics (VYGR) stock?

A

You can purchase shares of Voyager Therapeutics (NASDAQ:VYGR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Voyager Therapeutics (VYGR) competitors?

A

Other companies in Voyager Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Voyager Therapeutics (VYGR) stock?

A

Voyager Therapeutics has a consensus price target of $15.91.

Q

What is the current price for Voyager Therapeutics (VYGR)?

A

The stock price for Voyager Therapeutics (NASDAQ: VYGR) is $3.48 last updated August 25, 2026 at 4:00 PM EDT.

Q

Does Voyager Therapeutics (VYGR) pay a dividend?

A

There are no upcoming dividends for Voyager Therapeutics.

Q

When is Voyager Therapeutics (NASDAQ:VYGR) reporting earnings?

A

Voyager Therapeutics does not have any upcoming earnings scheduled.

Q

Is Voyager Therapeutics (VYGR) going to split?

A

There is no upcoming split for Voyager Therapeutics.

Q

What sector and industry does Voyager Therapeutics (VYGR) operate in?

A

Voyager Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.